---
title: "Ozempic (semaglutide) in type 2 diabetes: Drug interactions questions"
description: "Drug interactions questions on Ozempic (semaglutide) in type 2 diabetes, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What drug interactions does Ozempic have? 1 question quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/drug-interactions"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ozempic (semaglutide) in type 2 diabetes: Drug interactions questions

Manufacturer: Novo Nordisk Inc.  
Prescribing information: [Ozempic](https://www.novo-pi.com/ozempic.pdf), [Ozempic tablets](https://www.novo-pi.com/ozempictablets.pdf)

## Drug interactions

<a id="ozempic-drug-interactions"></a>

### What drug interactions does Ozempic have?

> “When initiating Ozempic<sup>®</sup>, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia
> Ozempic<sup>®</sup> causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor the effects of oral medications concomitantly administered with Ozempic<sup>®</sup>. Consider increased clinical or laboratory monitoring for medications that have a narrow therapeutic index or that require clinical monitoring”

Source: [OZEMPIC: GLP-1 RA for T2D, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic.html#:~:text=When%20initiating,or%20that%20require%20clinical%20monitoring)

> “In clinical pharmacology trials, 
> semaglutide did not affect the absorption of orally administered medications to any clinically 
> relevant degree [see Clinical Pharmacology (12.3)]. Nonetheless, caution should be exercised 
> when oral medications are concomitantly administered with OZEMPIC<sup>®</sup>.”

Source: [OZEMPIC: Ozempic®, page 4, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=4)

> “In vitro studies have shown very low potential for semaglutide to inhibit or induce CYP enzymes, 
> and to inhibit drug transporters.”

Source: [OZEMPIC: Ozempic®, page 5, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=5)

> “No clinically relevant drug-drug interaction with semaglutide (Figure 4) was observed based on 
> the evaluated medications; therefore, no dose adjustment is required when co-administered with 
> semaglutide.”

Source: [OZEMPIC: Ozempic®, page 5, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=5)

> “Levothyroxine exposure was increased 33% (90% CI: 1.25 to 1.42) when administered 
> with semaglutide tablets in a drug interaction study [see Clinical Pharmacology (12.3)].”

Source: [OZEMPIC: Ozempic®, page 5, captured 2026-11-12](https://www.novo-pi.com/ozempictablets.pdf#page=5)

## Related pages
- [Medical information: Ozempic (semaglutide): Type 2 diabetes](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes)
- [Indication](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/access-and-coverage)
